Senate Drops House Rider to Block Cannabis Rescheduling: Schedule III Path Clears in 2026

The biggest political risk hanging over federal cannabis rescheduling just got smaller. Senate appropriators have advanced their fiscal year 2027 Commerce, Justice, Science (CJS) spending bill without the House-passed rider that would have barred the Department of Justice from spending any funds to reschedule marijuana — a quiet but consequential rejection that keeps the Trump administration's Schedule III push alive heading into the June 29 DEA rescheduling hearing. The cannabis industry has watched the appropriations fight as the single biggest near-term threat to a decades-in-the-making federal reform, and the Senate's posture this week amounts to a green light, not a stoplight.

The decision lands four weeks after the DOJ's April 23 final order moving FDA-approved and state-licensed medical cannabis products to Schedule III, and just weeks before the DEA's expedited administrative hearing on broader rescheduling commencing June 29, 2026 at the agency's Arlington facility. Without the rider, the runway to a Schedule III determination for the entire cannabis plant — not just the carved-out medical bucket — stays open.

What the Senate Did and Didn't Do

The Senate Appropriations Committee passed its FY 2027 CJS spending bill this month and extended the longstanding rider that prevents the DOJ from using funds to interfere in state-level medical cannabis programs, a protection in place under various names since the original Rohrabacher–Farr amendment in 2014. What the committee declined to add was the language the House Appropriations Committee approved in a 32–28 vote in May: a sweeping prohibition stating that no funds "may be used to reschedule marijuana or to remove marijuana from the schedules" under the Controlled Substances Act.

That House provision, advanced by appropriators allied with Sub-Cabinet-level opponents of Trump's executive order, was the clearest legislative attempt yet to box in the executive branch on cannabis. It was also one of the few procedural vehicles that prohibitionists had left after the December 18, 2025 executive order on medical marijuana research, the April Schedule III final rule for state-licensed medical products, and the announcement of the June 29 expedited hearing for broader rescheduling. By omitting that language from the Senate base bill, the upper chamber has signaled that the appropriations track is not where this fight will be won.

The full House had earlier passed a separate spending package in a 397–28 vote that preserved state medical cannabis protections while excluding the rescheduling block — language that mirrors the Senate's current approach. Reconciliation between the two chambers' versions will play out over the summer, but the negotiating posture now favors the cleaner Senate text.

Why the Rider Matters More Than It Sounds

A funding rider does not change the underlying law, but it can effectively veto an agency's ability to act by denying the money required to do so. If the House language had made it into the final FY 2027 omnibus, the DEA could have held its June 29 hearing, written a record, and even issued a final rule, but the DOJ would be unable to spend a dollar processing the rule's implementation — Schedule III registrations, manufacturer quota allocations, research authorizations — for the duration of the fiscal year. That would have functionally paused any broader rescheduling for a year and given the next Congress and administration a chance to revisit the underlying policy.

The Senate's choice to omit the language means the DEA's rescheduling track stays funded. Cannabis operators, researchers, and state regulators can now plan around a hearing that proceeds on schedule, a record that closes by July 15, 2026, and a DEA final-rule timeline that — if the agency moves expeditiously, as the December 2025 executive order directs — could produce a broader Schedule III determination by late 2026 or early 2027.

The June 29 Hearing in Focus

The expedited administrative hearing the DEA scheduled for June 29 at 9 a.m. ET at the agency's Arlington hearing facility is the procedural mechanism for considering whether marijuana as a whole — not just FDA-approved formulations and state-licensed medical products — moves to Schedule III. Interested parties had until 11:59 p.m. ET on May 24, 2026 to file written notices of intention to participate, a deadline that falls one day after this article's publication.

The hearing will recess July 3 to allow participants and the public to mark the United States' 250th independence anniversary, then reconvene July 6 and conclude no later than July 15. Participants are expected to include MSOs, cannabis industry trade associations, public health groups on both sides of the issue, state regulators, and patient advocacy organizations. The DEA administrator will weigh the record and issue a final rule on broader rescheduling on a timeline now no longer threatened by an appropriations blackout.

What Cannabis Operators Should Watch Next

Three live threads will shape whether the Senate's procedural win this week translates into real Schedule III treatment for the broader cannabis plant.

First is the conference committee that will reconcile House and Senate appropriations text. The political baseline now favors the rider-free version, but riders have been added in conference before — particularly when prohibitionist members trade votes on unrelated provisions. Operators with policy budgets should track the conference negotiations closely through the summer.

Second is the DEA hearing itself. A record full of state medical cannabis successes, accepted-medical-use evidence, and academic research on lower-than-Schedule-I abuse potential will strengthen a broader Schedule III final rule. A record dominated by prohibitionist witnesses, by contrast, could push the DEA toward a narrower outcome that leaves recreational cannabis on Schedule I and only formally extends Schedule III to medical use cases.

Third is the parallel litigation track. Smart Approaches to Marijuana (SAM) and former Attorney General Bill Barr filed suit in April to block the Schedule III order for state-licensed medical cannabis on Administrative Procedure Act grounds. That case is at an early stage but could conceivably reach a preliminary injunction before the June 29 hearing concludes. The Senate's appropriations posture does not change the litigation calculus, but it does narrow the venues where prohibitionists can run out the clock.

What This Means for the Cannabis Industry

For multistate operators, the practical impact of the Senate's decision is that the Schedule III timeline they have been modeling against — December 2026 through Q1 2027 for broader rescheduling, plus a 270-day Section 280E phase-out for state-licensed adult-use operators if the DEA rule applies to them — remains in play. For investors, the rider risk that drove the early-May cannabis stock sell-off has materially eased, even if final passage of the CJS bill is still months away. For patients, particularly in non-medical states, the broader Schedule III path keeps alive the possibility that the federal–state cannabis policy gap narrows for the first time in a generation.

The fight is not over. House appropriators who lost the May committee vote will look for other vehicles, and conservative state attorneys general have telegraphed lawsuits of their own. But the appropriations rider was the simplest, cheapest, fastest way to derail rescheduling. With the Senate's CJS bill text in hand, the prohibitionist coalition has lost its quickest path.

Key Takeaways

• The Senate Appropriations Committee's FY 2027 CJS bill omits the House-passed language that would have blocked DOJ from spending money to reschedule marijuana, keeping the broader rescheduling track funded.
• The decision protects the DEA's June 29 expedited rescheduling hearing and the agency's ability to issue a final rule on broader Schedule III treatment in late 2026 or early 2027.
• A longstanding rider protecting state medical cannabis programs remains in both chambers' bills.
• Conference reconciliation and the June 29 hearing record are now the two biggest variables shaping the federal rescheduling endgame.
• Cannabis operators planning around a late-2026 broader Schedule III determination can keep that timeline in their models, though appropriations conference risk has not disappeared entirely.

Explore cannabis news, find dispensaries, and join the community at Budpedia.